Financial insights of BIIB

MyFinsight

For the quarter ending 2026-03-31, BIIB made $2,477,800K in revenue. $319,500K in net income. Net profit margin of 12.89%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	2,477,800	2,279,400	2,534,700	2,645,500
Gain on sale of priority review voucher, net	0	0*	0	0
Cost of sales, excluding amortization and impairment of acquired intangible assets	661,000	495,500	674,400	605,000
Research and development	539,000	509,400	436,100	399,000
Acquired in-process research and development, upfront and milestone expense	34,000	222,400	2,100	46,600
Selling, general and administrative	607,300	682,500	594,800	583,800
Amortization and impairment of acquired intangible assets	136,500	136,600	135,700	130,900
Collaboration profit sharing/(loss reimbursement)	74,200	69,900	87,200	75,000
(gain) loss on fair value remeasurement of contingent consideration	-	-8,400*	-	-
Impairment of rou asset	-	49,700*	-	-
Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease)	20,500	-	5,600	13,200
Restructuring charges	7,900	6,600	7,400	-700
Other (income) expense, net	-19,700	-154,400	-34,100	-48,700
Total cost and expense	2,100,100	2,335,400	1,977,400	1,901,500
Income before income tax (benefit) expense	377,700	-56,000	557,300	744,000
Income tax (benefit) expense	58,200	-7,100	90,800	109,200
Net income	-	-48,900*	-	-
Net income attributable to noncontrolling interests, net of tax	-	0*	-	-
Net income attributable to biogen inc	319,500	-48,900	466,500	634,800

Basic EPS	2.17	-0.333	3.18	4.33
Diluted EPS	2.15	-0.33	3.17	4.33
Basic Average Shares	147,200,000	146,800,000	146,600,000	146,500,000
Diluted Average Shares	148,400,000	148,000,000	147,100,000	146,700,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.